Author Q&A: YouTube Videos on Topical Steroid Withdrawal
The 10 most viewed YouTube videos on topical steroid withdrawal (TSW) overall had low reliability and quality, according to a study published in the November issue of the Journal of Drugs in Dermatology. The authors recommend dermatologists provide alternate, evidence-based resources for their patients, both in clinical practice and online, including YouTube.
To find out more about the quality …
The 10 most viewed YouTube videos on topical steroid withdrawal (TSW) overall had low reliability and quality, according to a study published in the November issue of the Journal of Drugs in Dermatology. The authors recommend dermatologists provide alternate, evidence-based resources for their patients, both in clinical practice and online, including YouTube.
To find out more about the quality … Continue reading "Author Q&A: YouTube Videos on Topical Steroid Withdrawal"
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Robyn Siperstein, a dermatologist in Boca Raton and Boynton Beach, FL. Watch as Dr. Siperstein explains how modalities such as microneedling can both increase and decrease pigment. Listen as she shares tips on getting the desired pigmentary effect. Hear about her pilot studies on combination therapies t … 
JDD authors Mihir Shah MD, Jenna Wald MD, and C. William Hanke MD MPH present a case of a patient with eruptive squamous cell carcinomas following treatment with Fludarabine to highlight not only the risk of cSCC in CLL patients and the increased risk for atypical cutaneous malignancies after treatment with systemic therapies such as fludarabine, but also to discuss treatment options for this … 
At ODAC 2023, we had the opportunity to learn about cicatricial alopecias from renowned dermatologist and hair expert Dr. Amy McMichael, Professor of Dermatology at Wake Forest University School of Medicine.
First, we considered a framework to check for cicatricial alopecias. This is particularly important because if we can identify cicatricial alopecia, we can make sure we are treating the rig … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 